Physician profile
Olivia Glidden
NPI 1750880589
$1,431.34
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,241 · 2022: $191.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $447.41 | 2021-2022 | |
| Daiichi Sankyo INC. | $249.93 | 2021 | |
| Therapeuticsmd, INC. | $130.71 | 2021 | |
| Pfizer INC. | $120.19 | 2021 | |
| Exeltis, USA INC. | $105.51 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $75.72 | 2021-2022 | |
| Novo Nordisk INC | $74.35 | 2021 | |
| Myovant Sciences INC. | $60.37 | 2021 | |
| Mylan Pharmaceuticals INC. | $58.17 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.78 | 2021-2022 | |
| Astellas Pharma US INC | $30.98 | 2021 | |
| Avion Pharmaceuticals | $26.24 | 2021 | |
| Merck Sharp & Dohme LLC | $16.98 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Glidden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.